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Abstract
Human genetic studies show that the voltage gated sodium channel 1.7 (Nav1.7) is a key
molecular determinant of pain sensation. However, defining the Nav1.7 contribution to noci-
ceptive signalling has been hampered by a lack of selective inhibitors. Here we report two
potent and selective arylsulfonamide Nav1.7 inhibitors; PF-05198007 and PF-05089771,
which we have used to directly interrogate Nav1.7’s role in nociceptor physiology. We report
that Nav1.7 is the predominant functional TTX-sensitive Nav in mouse and human nocicep-
tors and contributes to the initiation and the upstroke phase of the nociceptor action poten-
tial. Moreover, we confirm a role for Nav1.7 in influencing synaptic transmission in the dorsal
horn of the spinal cord as well as peripheral neuropeptide release in the skin. These findings
demonstrate multiple contributions of Nav1.7 to nociceptor signalling and shed new light on
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the relative functional contribution of this channel to peripheral and central noxious signal
transmission.
Introduction
Numerous genetic studies implicate Nav1.7 in the pathogenesis of distinct pain states (for
reviews see [1] [2]). In particular, loss-of-function mutations in SCN9A (the gene encoding
Nav1.7) have been identified in patients with congenital insensitivity to pain (CIP; [3]), whereas
gain-of-function mutations in SCN9A lead to chronic pain syndromes such as paroxysmal
extreme pain disorder (PEPD, [4]) and inherited erythromelalgia (IEM) [5] [6] [7] [8]. More-
over, expression of Nav1.7 in DRG neurons extends from the peripheral terminals in the skin
to the central terminals in the dorsal horn [9]. These studies present a clear link between
Nav1.7 function and pain sensation and raise the possibility that selective Nav1.7 inhibitors
might hold therapeutic potential as novel analgesics.
Despite the strong evidence implicating Nav1.7 in human pain genetic studies, a detailed
investigation of the role of Nav1.7 in nociception remains an important area of investigation.
Nav channels are essential for action potential initiation and upstroke in excitable cells. Out of
a repertoire of nine Navs (Nav1.1–1.9), five are expressed in varying levels in adult rodent
somatosensory DRG neurons: Nav1.1, Nav1.6, Nav1.7, Nav1.8 and Nav1.9 [10] [11] [12] [13].
Given the participation of multiple Navs in pain signalling, progress in delineating the individ-
ual roles of specific Nav isoforms in DRG neurons would be accelerated if subtype-selective
inhibitors were available.
In this study we characterize two novel arylsulfonamides: a clinical compound, PF-
05089771 (for a list of relevant clinical trials see [14]) and a structurally related preclinical tool
compound, PF-05198007. Both demonstrate high potency and a high degree of Nav subtype
selectivity, properties which are gained through a drug/channel interaction that is distinct from
that of the classical non-selective pore-blocking drugs such as local anaesthetics. We examined
the effects of selective Nav1.7 block in both in vitro and in vivo preparations with the principal
aim of exploring how Nav1.7 influences nociceptor function. Our findings establish a mecha-
nistic basis for Nav1.7 contribution to action potential electrogenesis in small diameter DRG
neurons and describe a functional role for Nav1.7 in controlling both neuropeptide release in
the peripheral compartment and synaptic transmission in the dorsal horn of the spinal cord.
Materials & Methods
Cell culture
Human embryonic kidney (HEK) 293 cells stably expressing human and mouse Nav subtypes
were commercially obtained (Millipore). Cells were maintained using minimum essential
medium (MEM) with Earle’s salts supplemented by 10% foetal calf serum, 2 mM L-glutamine,
1 mM sodium pyruvate, 1x non-essential amino acids and 0.4 mg/ml geneticin (G-418) and
kept at 37°C in a humidified atmosphere of 5% CO2. For manual patch clamp experiments,
cells were plated onto glass coverslips and used within 48 hours.
Ethical Approval
Mice were killed by cervical dislocation in accordance with Schedule 1 of the UK Government
Animals (Scientific Procedures) Act, 1986, following approval by the Animal Welfare and
Selective Inhibitors Reveal Role of Nav1.7 in Nociceptor Physiology
PLOS ONE | DOI:10.1371/journal.pone.0152405 April 6, 2016 2 / 22
Competing Interests: The authors declare no
competing financial interests. The authors declare a
commercial affiliation with Pfizer however this does
not alter the authors' adherence to PLOS ONE
policies on sharing data and materials.
Ethical Review Body, or euthanized by isoflurane in accordance with the National Institutes of
Health guide for the Care and Use of Animals following approval by the University of Virginia
Institute of Animal Care and Use Committee.
Mouse DRG preparation
Dorsal root ganglia (DRG) were isolated and dissociated according to a previously published
method [15]. Briefly, DRGs were obtained from all spinal locations and dissociated neurons
plated on glass coverslips pre-coated with poly-D-lysine/laminin (BD Biosciences) and left to
adhere for 1.5–2 hrs before flooding. Growth media consisted of Lebovitz L-15 Glutamax (Life
Technologies) supplemented with 10% FCS, 24 mM NaHCO3 and 38 mM glucose.
Human DRG preparation
Human DRGs (hDRGs) were surgically resected from US organ donors with full legal consent.
The hDRG culturing process has been previously described in detail [16]. Briefly, DRG neurons
were enzymatically dissociated and maintained in culture for up to 9 days prior to recording.
All hDRG tissue culture and experiments on hDRG neurons were conducted at Anabios Cor-
poration (San Diego, CA, USA).
Molecular Biology/ RNASeq
Approximately 300 small diameter neurons per sample (n = 4 animals, 2 samples per animal)
were picked off coverslips in PBS-/- (phosphate buffered saline without calcium or magne-
sium) (Invitrogen) using a patch pipette. RNA was extracted using the Qiagen RNeasy micro
kit as per the manufacturer’s protocol, including on-column DNase digestion. These control
samples were then converted to cDNA and amplified for 18 cycles using the SMARTer v3 kit
(Clontech). Libraries were quantified using the Nextera XT kit (Illumina), following a modi-
fied protocol (see Fluidigm C1 Single-Cell Auto Prep System manual). This protocol uses
lower input amounts than the standard Illumina method; 1.25 μl cDNA at 0.1 ng/μl per tag-
mentation reaction (5 μl total reaction volume). Negative controls were also prepared from
each animal by collecting bath solution; these produced no product at the end of amplifica-
tion or library preparation and hence were not sequenced. Libraries were quantitated individ-
ually using the Qubit High Sensitivity DNA assay (Thermo Fisher Scientific) and library
quantification kits (KAPA Biosystems) and pooled in equal amounts for single-end sequenc-
ing on an Illumina Nextseq 500. Reads were aligned using STAR (spliced transcripts align-
ment and reconstruction tool) and assigned to genomic features using Counts and Ensembl
gene annotations. Gene read counts were converted to fragments per kilobase per million
(FPKM).
Electrophysiology
Electrophysiological recordings were obtained from stably transfected HEK 293 cells, acutely
dissociated mouse DRG neurons, cultured human DRG neurons or mouse superficial dorsal
horn neurons using either an Axopatch 200B or Axopatch 700B amplifier (Molecular Devices),
or EPC-10 USB amplifier (HEKA). Small diameter mouse DRG neurons were identified as
those with a whole cell capacitance between 10–25 pF [17]. For human DRG neurons, patch
clamp recordings were obtained from small-to-medium diameter neurons (<60 μm), the
majority of which have previously been classified as nociceptors [16].
Patch pipettes were pulled from thick-walled borosilicate glass (Science Products) and had
open tip resitances of 1.5–5 MO when filled with intracellular solution (ICS; see below for
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composition). Data acquisition was performed using either pClamp v10 (Molecular Devices)
or PatchMaster (HEKA) software.
Voltage clamp. HEK cells or mouse DRG neurons were continuously superfused with
extracellular solution (ECS) containing (in mM): 30 NaCl, 110 Choline Cl, 3 KCl, 0.8 MgCl2, 1.8
CaCl2, 0.05 CdCl2, 10 Glucose, 10 HEPES, 5 Sucrose (300–310 mOsm, titrated to pH 7.4 with
TEA-OH). The patch pipette (intracellular) solution (ICS) contained (in mM): 5 NaCl, 135 CsF,
10 CsCl, 2 MgATP, 10 HEPES, 5 EGTA (290–300 mOsm, titrated to pH 7.2 with KOH). For
human DRG recordings the following solutions were used (ECS in mM):150 NaCl, 4 BaCl, 2
CaCl2, 1 MgCl2, 0.1 CdCl2, 10 Glucose, 10 HEPES, (300–310 mOsm titrated to pH 7.3 with Na-
OH). ICS in mM: 140 CsF, 10 NaCl, 1 EGTA, 1 MgCl2, 10 HEPES, 10 glucose, (290–300 mOsm,
titrated to pH 7.3 with Cs-OH). Series resistance compensation was routinely applied to at least
75%. Before acquisition, 20 ms pulses to 0 mV were repeatedly applied (0.05 Hz) from Vm =
-120 mV until stable current responses were obtained. All experiments were carried out at room
temperature (21–24°C). IC50 values were generated in HEK 293 cell lines by voltage clamping at
-120 mV before stepping to the V0.5 of inactivation for 5 seconds in order to accumulate com-
pound binding. This was followed by a 100 ms return to -120 mV preceding a 20 ms test step to
0 mV. Cells with large TTX-S currents (>5 nA mouse,>8 nA human) and cells with series
resistance values greater than 15 MO, or variable series resistance were omitted from analysis.
Current clamp. ECS contained (in mM) 135 NaCl, 4.7 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES
and 10 glucose (300–310 mOsm, pH 7.4 with NaOH). ICS contained (in mM) 140 KCl, 0.5
EGTA, 5 HEPES, and 3 Mg-ATP, (pH 7.3 with KOH, 300–305 mOsm). Single action potentials
were evoked from Vm -70 mV by a 20 ms suprathreshold current step (0.1 Hz).
Action potential voltage clamp. Recordings were performed as described in Blair & Bean
(2002). Briefly, the internal solution contained (in mM): 140 K-Mes, 13.5 NaCl, 1.6 MgCl2,
0.09 EGTA, 9 HEPES, 0.9 glucose, 14 Tris-creatine PO4, 4 Mg-ATP, and 0.3 Tris-GTP (285–
300 mOsm, pH 7.2 with KOH). The ECS was identical to that used for current clamp record-
ings (see above). Action potentials were recorded in current clamp mode following a 20 ms cur-
rent injection from a Vm of -70 mV. The same cell was then examined under voltage-clamp
(-70 mV) whereby the recorded action potential was used as the voltage command. Series resis-
tance was compensated for by up to 80%.
PatchXpress automated electrophysiological recordings
Extracellular solution contained (in mM): 40–138 NaCl, 0–98 choline chloride, 2 CaCl2, 5.4 KCl,
1 MgCl2, 10 glucose, and 10 HEPES, (295–310 mOsm, pH 7.4 with NaOH). Internal solution con-
tained (in mM): 135 CsF, 5 NaCl, 2 MgCl2, 10 EGTA, 10 HEPES (285–295 mOsm, pH 7.3 with
NaOH). HEK 293 cells constitutively expressing human sodium channels were grown as above to
50–80% confluency and harvested by trypsinization. Trypsinized cells were washed and resus-
pended in extracellular buffer at a concentration of 106 cells/ml. The onboard liquid handling
facility of the PatchXpress was used for dispensing cells and application of test compounds, where
washout periods were limited to a maximal duration of 5–10 min. The effect of PF-05089771 was
evaluated with voltage protocols identical to those used for conventional patch clamp. A detailed
rationale and description of the development of the PatchXpress protocol has been previously
described [18]. Previous characterization of the PatchXpress platform demonstrated the ability to
generate Nav channel pharmacology comparable to conventional patch clamp data[18].
Spinal cord slice preparation and electrophysiology
Male adult CD1 mice were terminally euthanized and the spinal column was removed and sub-
merged in chilled (4°C) artificial cerebrospinal fluid solution (aCSF) comprised (in mM): 125
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NaCl, 25 NaHCO3, 10 glucose, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 0.5 L-ascorbic acid
and 2 pyruvate (300–310 mOsm, bubbled with a 95%, 5% O2/CO2 gas mixture). Following
lumbosacral laminectomy, the dura mater and pia-arachnoid membrane were carefully
removed leaving intact dorsal roots. Para-saggital slices (400 μm) were prepared using a Vibra-
tome 1000 Plus sectioning system (Vibratome) and stored in warm oxygenated (37°C) aCSF
for 35 mins after which slices were kept at room temperature until required. Slices were trans-
ferred to a recording chamber and perfused at 2 mL/min with aCSF heated to 32°C. For experi-
ments in which test compound was applied to the dorsal roots only, a recording chamber was
used that consisted of two separate baths, each with their own perfusion inlets and outlets. The
separate chambers were connected via tunnels that allowed the dorsal root to pass across and
was then sealed using silicone grease. Both chambers were independently perfused at 2 mL/
min with aCSF heated to 32°C. Whole-cell voltage clamp recordings were obtained from visu-
ally identified substantia gelatinosa neurons present in lamina II. ICS containied (in mM): 120
K gluconate, 10 NaCl, 2 MgCl2, 0.5 K2EGTA, 10 HEPES, 4 Na2ATP, 0.3 NaGTP, 20 biocytin
(285–300 mOsm, pH adjusted to 7.2 with KOH).
Synaptic responses were evoked using a glass suction electrode to deliver a 400 μs stimulus
of varying current amplitude (1 to 3.2 mA) applied every 15 sec via a digital stimulator (Digiti-
mer Ltd, Hertfordshire, UK). Aδ-fiber EPSCs were distinguished from C-fiber EPSCs by the
differences in latency to evoke an EPSC with C-fiber EPSC’s having longer latency than Aδ-
fiber EPSC’s. Only monosynaptic evoked excitatory post synaptic currents (EPSC’s) were
recorded. Perfusion to the spinal cord section also contained 50 μM picrotoxin and 50 μM
strychnine to record only AMPA mediated EPSCs. Membrane signals were filtered at 2 kHz
and sampled at 33 kHz.
Synaptosome preparation and CGRP release assay
Male adult CD1 mice were terminally euthanized as described above, the spinal column
removed and submerged in ice-cold ACSF bubbled with a 95/5% O2/CO2. A lumbosacral lami-
nectomy was performed and a segment of lumbar spinal cord was removed into a petri dish
containing ice-cold pre-oxygenated aCSF. The dura mater, ventral and dorsal roots and the
pia-arachnoid membrane were removed. A small segment of the spinal cord containing only
the lumbar region (L4–L5) was dissected free, weighed and placed into ice-cold homogeniza-
tion buffer composition (mM) 0.32 M sucrose, 10 mMHEPES (pH 7.4, bubbled with 100%
O2). Spinal cord tissue was homogenized in buffer using 20 strokes of a glass/glass hand
homogenizer. The crude homogenate was diluted with 3 mL of ice-cold homogenization buffer
and centrifuged at 1000 x g for 5 mins at 4°C. Synaptosomes were isolated from the supernatant
by an additional centrifugation at 20,000 x g for 2 mins at 4°C. The synaptosomal pellet was
resuspended in 3 mL of Krebs buffer with composition (in mM): NaCl 118, KCl 2.4, CaCl2 2.4,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 10, pH 7.4 (bubbled with 95% O2 and 5% CO2).
Protein quantification was performed on the synaptosomal solution using the Bradford colori-
metric protein assay and bovine serum albumin standards. Samples were diluted to obtain a
final concentration of 0.1 mg mL-1 for CGRP evaluation and 100 μL samples of the synapto-
somal solution was pipetted into eppendorfs. Synaptosomes were incubated at 37°C for 10
mins in the presence of test compounds or DMSO (1 μl total volume). Synaptosomes were
stimulated using Veratridine 10 μM in the presence of Thiorphan (10 μM) and incubated for a
further 10 mins at 37°C. Samples were then filtered using 0.22 μM filters and 100 μl of the fil-
trate was transferred to CGRP ELISA plate (Bertin Pharma) and assayed according to the man-
ufactures instructions. Absorbance values were obtained using a microplate reader (Biorad
model 680) at a wavelength of 415 nm.
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Capsaicin flare
Adult Male C57Bl/6J Wild type (WT) and Nav1.7Nav
1.8Cre mice were kept under a 12h light/
dark cycle (lights on at 07:00) with food and water ad libitum. Up to 24h prior to dosing mice
were shaved on both flanks and returned to their home cages. Subsequently, mice were grouped
randomly and dosed orally with 1 or 10 mg/kg PF-05198007 or vehicle as appropriate (n = 8
per group). At 1h 15mins post dose mice were placed in an anesthetic chamber and anesthe-
tized with a 5% isoflurane/O2 mixture. Anesthesia was maintained using a nose cone and ani-
mals transferred to a homeothermic blanket for the duration of the procedure. Laser Doppler
flowmetry scans (MoorLDI apparatus, Moor Instruments Ltd, Axminster, United Kingdom)
were taken from an area of the flank approximately 1.6cm2. Baseline scans were recorded for
35 mins, following which 50 μl of a 0.1% capsaicin (Sigma) dissolved in 100% ethanol was
administered topically to the centre of the flank scan area using a 12mm polypropylene coated
aluminium Finn chamber on Scanpor tape (Biodiagnostics Ltd, Worcestershire) for 10 min.
Laser Doppler flowmetry scans were recorded for 55 mins post-removal of the Finn chamber.
Laser Doppler flowmetry data was analyzed using proprietary software (MoorLDI, version
5.2). Baseline blood flow was calculated as the mean of the final 5 scans prior to capsaicin
application.
Data analysis
Patch clamp electrophysiological data analyses were performed using either pClamp v10 soft-
ware (Molecular Devices), PatchMaster software (HEKA) or Spike 2 v7 (CED). Action poten-
tial parameters (voltage threshold, peak amplitude, upstroke slope, width at threshold) were
determined using a bespoke Spike 2 v7 analysis script courtesy of CED. Data are presented as
mean ± standard error of the mean (SEM) Statistical comparisons were made using the paired
Student’s t-test, one-way analysis of variance (ANOVA) with Bonferroni or Tukey’s post-tests,
or ANOVA on ranks.
Drugs and reagents
PF-05089771 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-
(1,3-thiazol-4-yl)benzenesulfonamide and PF-05198007 [4-(2-(3-amino-1H-pyrazol-4-yl)-4-
(trifluoromethyl)phenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide] were syn-
thesized by Worldwide Medical Chemistry, Pfizer Worldwide Research & Development. Drugs
were made up in 100% DMSO as a 10 mM stock, except for tetrodotoxin (TTX, Nanning Leaf
Pharmaceuticals, Canada) which was dissolved in water. Final working concentrations were
made on the day of the experiments in ECS.
Results
Discovery, potency and selectivity of PF-05089771 and PF-05198007
The identification of the clinical compound PF-05089771 and the closely related preclinical
compound PF-05198007 as potent and selective inhibitors of the human Nav1.7 (hNav1.7)
channel resulted from iterative structure activity relationship—based refinement of a series of
novel arylsulfonamide Nav channel inhibitors. Arylsulfonamide inhibitors of Nav1.7 (as exem-
plified by PF-05089771, Fig 1A) were identified as inhibitors of partially inactivated hNav1.7
channels by electrophysiological testing on the PatchXpress (Fig 1B and 1C) with a voltage pro-
tocol that set the holding potential to the empirically determined half-inactivation voltage for
each cell (Fig 1B). For hNav1.7 in HEK 293 cells the V1/2 of inactivation ranged from -54 mV
to -96 mV with a mean value of -77.7 mV (n = 291). State-dependence of block was likewise
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Fig 1. PF-05089771 is a potent, state-dependent and selective inhibitor of Nav1.7. A. Structure of PF-05089771 (4-(2-(3-amino-1H-pyrazol-4-yl)-
4-chlorophenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)benzenesulfonamide) B. Representative PatchXpress current recordings illustrating the near-complete
block following 300 nM PF-05089771 application to half-inactivatedWT hNav1.7 channels (97% ± 3%, n = 10) which was partially reversed following a 5 min
washout duration. In contrast there was minimal block following application of 300 nM PF-05089771 to resting WT hNav1.7 channels (5% ± 3%, n = 4). Inset:
PatchXpress voltage protocols for half-inactivation (upper) and resting state (lower). For a full description of the voltage protocols see Methods. C. Block of
half-inactivatedWT hNav1.7 channels (n = 6–22 per concentration) was nearly 1000-fold more potent than resting channels (n = 4–11 per concentration) (11
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assessed. In order to measure compound block at resting state, the original voltage protocol
was modified to remove the conditioning step to the half-inactivation voltage, retaining all
other aspects of the drug addition and voltage-control parameters (Fig 1B). Under these condi-
tions the concentration-response relationship revealed an IC50 of 11 nM for half-inactivated
channels and an IC50 of ~10 μM for resting channels, nearly 1000-fold less potent than seen
with half-inactivated channels (Fig 1B and 1C).
Nav1.7 undergoes two independent alternative splicing events leading to the production of
four splice isoforms of human Nav1.7 [19]. Implementing similar protocols as described above,
PF-05089771 blocked all Nav1.7 splice variants with similar potency (Fig 1D, Table 1). Evalua-
tion of the blockade of more distantly related channels, specifically, L-type calcium channels,
KvLQT and hERG potassium channels, demonstrated that PF-05089771 is highly selective
over these channels with IC50 values determined to be 10 μM. No blockade of the human and
cynomolgus TRPV1 receptors was observed at tested concentrations of PF-05089771 up to 20
and 10 μM, respectively. (S1 Table).
To examine the molecular basis of the Nav1.7 interaction with this novel inhibitor we mea-
sured PF-05089771 inhibition of channels that were mutated to change (1) the natural molecu-
lar determinant for TTX sensitivity in domain 1 (hNav1.7 TTX-R, Y362S) [20], (2) local
anesthetic binding residues (hNav1.7 LA Mut, F1737A/Y1744A) [21] and (3) a recently identi-
fied small molecule binding site in VSD4 (hNav1.7 M1,2,3 Y1537S/W1538R/D1586E) [22].
Data in Fig 1E show that the potency of PF-05089771 was not substantially affected (<3-fold)
by mutation of either the TTX or local anesthetic binding sites hNav1.7 (IC50 11 ± 1.3 nM);
hNav1.7 TTX-R, (IC50 21.6 ± 1.2 nM); hNav1.7 LA Mut, (IC50 4.7 ± 1.2 nM). However, PF-
05089771 potency was reduced ~100 fold (IC50 1.15 ± 1.2 μM) by the hNav1.7 M1,2,3 muta-
tion, indicating interaction of PF-05089771 with the domain 4 VSD (VSD4).
Based on differences in the cross species sequence homology at the VSD4 binding site for
PF-05089771, the possibility of species-dependent changes in potency was investigated. The
Nav1.7 orthologues were cloned from rat, mouse, dog and cynomologus macaque and each was
heterologously expressed in HEK 293 cells to facilitate the cross species comparison. PF-
05089771 was found to inhibit the sodium currents of mouse, dog and cynomologus macaque
Nav1.7 with potency indistinguishable from that of the human channel (Table 2). However, the
rat Nav1.7 potency was significantly decreased (IC50 168 nM, 15.3-fold lower than human)
compared to all other tested species, consistent with sequence divergence of the putative PF-
nM vs 10 μM). D. Potency of PF-05089771 was similar across hNav1.7 splice variants. IC50 values and Hill slopes are provided in Table 1. Data points
represent n = 2–9 observations per concentration. E. PF-05089771 activity is impacted by mutation of a novel interaction site and not by local anaesthetic or
toxin binding sites. Data points represent n = 3–6 observations per concentration except for hNav1.7 where n = 6–22 observations per concentration. F.
Potency of PF-05089771 was assessed on orthologous channels cloned from common preclinical species. IC50 values and Hill slopes are provided in
Table 2. Data points represent n = 2–28 observations per concentration. G. PF-05089771 is a selective Nav1.7 subtype-selective inhibitor. Selectivity was
assessed across a collection of heterologously expressed human Navs on PatchXpress at the unique half inactivation voltage for each channel. Hill slopes
and IC50 values are provided in Table 3. Data points represent n = 3–12 observations per concentration except for hNav1.7 where n = 6–22 observations per
concentration. Selectivity over the TTX-R Nav1.5 and Nav1.8 channels was greater than 1000-fold.
doi:10.1371/journal.pone.0152405.g001
Table 1. Potency of PF-05089771 across hNav1.7 splice variants.
5N11L 5A11S 5A11L 5N11S
IC50 (nM) 33 20 16 11
HillSlope 1.4 0.8 0.9 1.0
SEM 1.1 1.2 1.2 1.1
doi:10.1371/journal.pone.0152405.t001
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05089771 binding residues within the VSD4 in rat Nav1.7 (H1547/W1548R/E1595, Fig 1F,
Table 2) [22].
Nav channel isoform selectivity was also assessed using the half-inactivation voltage for each
cell in hNav1.x channels stably expressed in HEK293 cells. PF-05089771was determined to be
more than 1000-fold selective over tetrodotoxin-resistant (TTX-R) Nav1.5 and Nav1.8 channels
(IC50s>10 μM) and exhibited a range of selectivity over TTX-sensitive (TTX-S) channels
(10-fold for Nav1.2 to 900-fold for Nav1.3 and Nav1.4) (Fig 1G, Table 3). Subsequently, these
highly potent and selective Nav1.7 inhibitors permitted us to interrogate Nav1.7 in physiologi-
cal preparations without pharmacological interference with other Nav channel isoforms.
Nav1.7 is the major TTX-sensitive Nav channel in small-diameter DRG
neurons
To investigate the relative abundance of Nav1.7 in nociceptors,we examined the Nav repertoire
at the mRNA level in acutely dissociated small-diameter mouse DRG neurons using whole-
transcriptome RNA sequencing. Fig 2A shows significant expression of mRNA for Nav1.7,
Nav1.8 and Nav1.9 suggesting that Nav1.7 is the predominant TTX-S isoform. The functional
influence of Nav1.7 compared to other TTX-S Nav subtypes present in mouse DRG neurons
was then assessed. For these experiments, PF-05198007 was used—a preclinical tool compound
with an identical pharmacological selectivity profile (and marginal potency differences) to
those described for PF-05089771, (Fig 2B and 2C) including slow kinetics of block which was
fully reversible (using a resting-state protocol) after 20–30 min. Using whole-cell patch-clamp,
the TTX-S current in small diameter mDRG neurons was isolated by application of the Nav1.8
blocker A-803467 (1 μM) [23]. Of the total Na+ current, an average of 34.1 ± 3.0% was blocked
by A-803467 and the remaining current was abolished by TTX (i.e. the TTX-S current, n = 41).
Application of PF-05198007 (30 nM) blocked on average 83.0 ± 2.7% of the total TTX-S cur-
rent indicating that the major TTX-S conductance is carried through Nav1.7 channels in small-
diameter mouse DRG neurons (n = 35, Fig 2D, 2E and 2F).
Nav1.7 contributes to action potential threshold and upstroke in small
mDRG neurons
Previous studies have suggested that Nav1.7 contributes to electrogenesis by increasing the prob-
ability that the cell will reach action potential threshold [24] [20] [25]. To investigate this,
Table 2. Potency of PF-05089771 assessed at orthologous channels from selected species.
cynNav1.7 dogNav1.7 ratNav1.7 musNav1.7
Slope 1.1 0.9 1.1 0.8
IC50 (nM) 12 13 171 8
IC50 SEM (nM) 4.9 5.3 1.2 1.2
doi:10.1371/journal.pone.0152405.t002
Table 3. Activity of PF-05089771 at human voltage-gated sodium channel isoforms.
Nav1.1 Nav1.2 Nav1.3 Nav1.4 Nav1.5 Nav1.6 Nav1.7 Nav1.8
Slope 0.7 1.4 1.2 1.1 1.0 0.9 1.0
IC50(μM) 0.85 0.11 11 10 25 0.16 0.011 > 10
SEM 1.2 1.1 1.2 1.2 1.1 1.2 1.3
doi:10.1371/journal.pone.0152405.t003
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current-clamp recordings were made from acutely dissociated mDRG neurons in which a series
of sequentially larger current steps was applied in order to accurately determine the action
potential rheobase. PF-05198007 significantly increased rheobase (control: 173 ± 37 pA vs PF-
05198007: 239 ± 47 pA, n = 7, p< 0.01, ANOVA, Fig 3), an effect that returned to the control
level following washout (control: 173 ± 37 pA vs wash: 176 ± 35 pA, p> 0.05, ANOVA, Fig 3B
and 3C). The effect of PF-05198007 on rheobase confirms that Nav1.7 is important in setting
action potential threshold in small-diameter DRG neurons. Subsequently, the effect of PF-
05198007 on additional parameters of the action potential waveform was investigated. In cur-
rent-clamp mode, single action potentials were evoked from -70 mV at 10 second intervals by
20 ms current steps to approximately 1.3 x rheobase. The aim of this protocol was to provide
reliable action potential generation whilst minimizing any contaminating influence of the
Fig 2. Nav1.7 is the major TTX-sensitive Nav channel in small diameter mDRG neurons. A. RNASeq
analysis of Nav channel mRNA from pooled small diameter mouse DRG neurons. B. Structure of PF-
05198007 (4-(2-(3-amino-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy)-5-chloro-2-fluoro-N-(thiazol-4-yl)
benzenesulfonamide C. Patch clamp data showing concentration-response relationship for PF-05198007
assessed against recombinantly expressed mouse Nav1.7, Nav1.6 and Nav1.1 (IC50, Slope: 5.2 nM, 1.1; 149
nM, 1.5; 174 nM, 0.7 respectively; n = 3–4 per concentration). D. Representative patch clamp current traces
of peak sodium current from small diameter mouse DRG neurons in the presence of A-803467 and following
concurrent application of PF-05198007 and TTX. E. Representative peak TTX-S current vs time plot before
and after 30 nM PF-05198007 and 500 nM TTX. G. Scatter plot of cell capacitance vs Nav1.7/TTX-S ratio
(n = 35). Note that in every cell tested, Nav1.7 provided the predominant TTX-S sodium conductance.
doi:10.1371/journal.pone.0152405.g002
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current step to the action potential waveform. In 6/13 small-diameter DRG neurons tested, PF-
05198007 (30 nM) application resulted in action potential failure (Fig 4A) with the remaining 7
cells continued to exhibit action potential firing in the presence of PF-05198007. In the case of
the latter, PF-05198007 impacted the action potential waveform whereby action potentials
Fig 3. PF-05198007 increases action potential rheobase in small diameter mDRG neurons. A.
Overlayed representative voltage traces in response to graded current step injections before (blue) and after
PF-05198007 application (red). Current step stimulations are shown below. B. Example timecourse of
change in rheobase following PF-05198007 application and washout. C. Summary bar graph, n = 8 neurons,
** p < 0.01, ANOVA. Data are shown ±SEM.
doi:10.1371/journal.pone.0152405.g003
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appeared delayed and were of smaller amplitude relative to control (Fig 4B). The representative
phase plot in Fig 4C reveals the extent of waveform attenuation in the presence of PF-05198007.
In particular, there was a reduction in the rate of voltage change during both the upstroke and
repolarization phases, coupled with a reduction in the peak amplitude. PF-05198007 application
Fig 4. Nav1.7 controls action potential threshold and contributes to the rising phase. A. Example
current clamp voltage traces in which PF-05198007 application resulted in action potential block. Single
action potentials were evoked by a 20 ms suprathreshold current step at 0.1 Hz. The scale bar refers to the
voltage traces whereas the start-to-start interval is 10 s. Inset: pie chart showing PF-05198007 (30 nM)
resulted in complete action potential block in 6/13 neurons tested. B. Overlayed example action potential
traces recorded from a neuron that exhibited partial block in response to PF-05198007 application. C. Phase
plot of the action potential depicted in B. D. PF-05198007 depolarized the action potential voltage threshold
and decreased both the peak amplitude and upstroke slope (n = 7 neurons, * p < 0.05, ** p < 0.01, paired t-
test, data shown ±SEM). E. Example traces from an action potential voltage clamp experiment. Upper: the
command action potential. Middle: overlayed current traces before (blue) and after PF-05198007 (30 nM,
red). Lower: current subtraction revealing the current sensitive to block by PF-05198007. F. Example time-
course of PF-05198007 effects on peak inward current. G. Scatter plot showing peak inward current for
individual recordings as well as mathematical mean ± SEM before and after PF-05198007, n = 8 neurons,
*** p < 0.001, paired t-test.
doi:10.1371/journal.pone.0152405.g004
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resulted in a significant depolarization of action potential threshold (control: -27.8 ± 2.0 mV vs
PF-05198007: -22.8 ± 1.6 mV, n = 10, p< 0.01) and a reduction in both spike amplitude (con-
trol: 43.0 ± 3.3 mV vs PF-05198007: 37.7 ± 3.9 mV, n = 10, p< 0.05) and upstroke slope (con-
trol: 137 ± 19 mV/ms vs PF-05198007: 86 ± 11 mV/ms, n = 10, p< 0.01, Fig 4D). In addition to
confirming an important contribution to action potential threshold, these findings might sug-
gest that Nav1.7 also contributes to the action potential upstroke phase. Alternatively, the
changes in voltage trajectory that accompany a loss of threshold current might affect subsequent
non-Nav1.7 sodium channel conductances so that the effects of PF-05198007 on amplitude and
upstroke slope occur as an indirect consequence of Nav1.7 block. We tested this hypothesis by
performing voltage-clamp experiments on mDRG neurons in which an action potential
recorded from the cell under study was used as the command voltage (action potential voltage-
clamp; Blair and Bean, 2002). The inward current component of the overlayed traces in Fig 4E
(middle panel) shows an increased latency following PF-05198007 application accompanied by
a decrease in the peak amplitude (in both cases p< 0.05, n = 7, Fig 4E, 4F and 4G). The subtrac-
tion of the residual current in the presence of PF-05198007 from the control current (Fig 4E
lower panel) reveals an inward current that approximates to the Nav1.7 current flowing during
the action potential. Comparison of this current time-course to that of the the action potential
waveform illustrates that the peak of the PF-05198007-sensitive current occurred towards the
peak of the action potential rising phase, suggesting a role for Nav1.7 not only in defining
threshold but also in the action potential rising phase.
The role of Nav1.7 in human DRG neurons
To test whether our findings from isolated mouse DRG neurons extend to those derived from
humans, electrophysiological recordings were made from small-to-medium diameter (<60 μm)
DRG neurons surgically resected from human donors (hDRG neurons) and maintained in cell
culture for up to 9 days. A recent study has reported that the majority of this cell population
exhibit hallmarks of nociceptors [16]. Fast-inactivating TTX-S sodium currents were observed
in all hDRG neurons (n = 16, Fig 5A). For these currents, the midpoint of the voltage activation
and inactivation was –32.2 ± 0.8 mV and -71 ± 1.7 mV respectively (Fig 5B) compared with
-22.0 ± 1.7 mV and -73.4 ± 1.5 mV recorded from human Nav1.7 recombinantly expressed in
HEK 293 cells (p< 0.05; n = 9–10, data not shown). To assess the contribution of Nav1.7 in
human DRG neurons directly, TTX-S currents were again isolated using A-803467 and
recorded before and after application of PF-05089771. At a selective concentration (30 nM), this
Nav1.7 inhibitor blocked the majority of TTX-S current (75.5 ± 10.5%, n = 5, Fig 5D) whilst 100
nM resulted in complete block (Fig 5C and 5D). The IC50 for TTX-S current block in hDRG
neurons was 8.4 ± 1.2 nM (n = 5–8 per concentration) vs 11 ± 1.2 nM for recombinantly
expressed hNav1.7. Together, these data confirm that Nav1.7 underlies the majority of TTX-S
current in cultured nociceptive hDRG neurons. We next explored how Nav1.7 contributes to
electrogenesis in these cells. Fig 5E shows a voltage trace from a current-clamp recording in
which we utilised the same current stimulus protocols as described for mDRG neurons (i.e.
action potentials were evoked once every 10 seconds by 20 ms depolarizing current steps of
amplitude just exceeding rheobase with the prestimulus Vm maintained at -70 mV). Under
these recording conditions 30 nM PF-05089771 blocked action potentials in 3 out of 7 neurons
and 100 nM resulted in action potential failure in 5 out of 8 cells tested (Fig 5E and 5F).
Contribution of Nav1.7 to nociceptor signalling in the spinal cord
Within mouse spinal cord slices, stimulation of dorsal roots evoked both Aδ and C fiber excit-
atory post-synaptic currents (EPSCs) in substantia gelatinosa (SG) neurons of the superficial
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dorsal horn that were completely abolished by NBQX (5 μM) and TTX (500 nM; data not
shown). Application of PF-05198007 to the whole preparation comprising spinal cord with
attached dorsal root (30 nM; 20–30 mins) caused a significant inhibition of Aδ-fiber (by
46.9 ± 5.4%; n = 4, p< 0.05; ANOVA) and C-fiber (53.7 ± 10.1%; n = 8, p< 0.05; ANOVA,
Fig 6A and 6B) evoked EPSC amplitudes. Under current-clamp conditions, electrical stimula-
tion of the dorsal root evoked a single action potential in SG neurons. In the presence of 30 nM
Fig 5. Evidence for functional Nav1.7 in human DRG neurons. A. Representative TTX-S current traces
(recorded in the presence of 1 μMA-803467 and following graded voltage steps from -110 mV to 10 mV. B.
Voltage dependence of activation (red, n = 4 for each voltage) generated from the protocol described in A and
steady state fast inactivation (blue) generated by conditioning 500 msec prepulses to voltages between -110
mV and +10 mV followed by a test pulse to 0 mV from a holding potential of -110 mV (n = 4 for each voltage).
Both datasets are fitted with Boltzmann functions. C. Representative timecourse relationship for peak TTX-S
current following the application of 100 nM PF-05089771 and 500 nM TTX. D. Concentration-response
relationship for PF-05089771 block of TTX-S current (IC50, slope: 8.4 nM, 1.1; n = 3–6 per concentration) E.
Example voltage traces from a current clamp recording. Single action potentials were evoked by a 20 ms
suprathreshold current step at 0.1 Hz. The scale bar refers to the voltage traces whereas the start-to-start
interval is 10 s. F. Summary pie charts showing that the application of 30 and 100 nM PF-05089771 resulted
in action potential block in 3/7 and 5/8 DRG neurons respectively.
doi:10.1371/journal.pone.0152405.g005
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PF-05198007, such evoked action potentials were abolished in 8 out of 9 neurons tested (Fig
6A, lower trace). Action potentials were also evoked by injection of depolarizing current into
SG neurons. Application of PF-05198007 (30 nM) had no effects on action potentials evoked
in this manner (n = 6; Fig 6C) suggesting a presynaptic site of action for PF-05198007. To
Fig 6. PF-05198007 acts peripherally and centrally to influence neurotransmitter release. A. Upper:
representative evoked EPSCs during control (blue) and after 30 mins PF-05198007 application (red). Lower:
representative synaptically evoked action potential trace (blue) recorded in SG neurons of the dorsal horn
following dorsal root stimulation. PF-05198007 (20 mins) abolished synaptically evoked action potentials
(red). B. Example time course of EPSC block following PF-05198007 application to the whole preparation. C.
Action potentials induced via current injection steps in SG neurons were not abolished by PF-05198007 (30
nM). Representative voltage traces are shown following current injection steps of -20, 0 and 50 pA before
(blue traces) and after (red traces) PF-05198007 application. Line chart shows change in firing frequency
(Hz) during control and after application of PF-05198007 for all neurons tested (n = 5, p > 0.05, paired t-test).
D. Example time course of EPSC block following PF-05198007 application to the dorsal root alone. E.
Representative EPSC traces and summary bar graph showing that the application of PF-05198007 (30 nM)
to the dorsal root alone inhibited C-fibre mediated EPSCs and resulted in a significant conduction delay
(n = 7, * p < 0.05; ANOVA on Ranks). F. PF-05198007 (30 nM; n = 15: 100 nM; n = 19) reduced veratridine
evoked CGRP release in spinal cord synaptosomes. Reduction was compared with mexilitine (100 μM;
n = 19), Ca2+ free conditions (n = 8) and TTX (500 nM; n = 6) (Data are shown ±SEM; * p < 0.05; ANOVA on
Ranks).
doi:10.1371/journal.pone.0152405.g006
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investigate the influence of axonally expressed Nav1.7 we used a dual perfusion bath that
allowed PF-05198007 to be applied to the dorsal root specifically, without exposure to the spi-
nal cord itself. Application of PF-05198007 (30 nM) to the dorsal root inhibited C-fiber evoked
EPSCs by 87 ± 9% (n = 7; Fig 6D and 6E), and caused a significant (p< 0.05) delay in the
latency of the C-fiber mediated EPSC (Fig 6E) suggesting a role for Nav1.7 in axonal action
potential conduction.
To investigate the role of Nav1.7 in neuropeptide release from primary afferent central ter-
minals we investigated the actions of PF-05198007 on veratridine-induced CGRP release from
synaptosomes prepared from L4/L5 spinal cord sections (Fig 6F). Both PF-05198007 (30 nM &
100 nM) and mexiletine (100 μM) significantly reduced veratridine evoked CGRP release (in
all cases p< 0.05; ANOVA on Ranks).
PF-05198007 reduces the capsaicin flare response in WT, but not
Nav1.7
Nav1.8Cre mice
To understand whether Nav1.7 contributes to neuropeptide release at the free nerve endings of
nociceptors in the skin, in addition to CGRP release from central primary afferent terminals,
we investigated the effects of the PF-05198007 on the capsaicin flare response in vivo. For WT
mice, application of capsaicin (0.1%) induced a sustained flare response (Fig 7). Oral pre-treat-
ment with the Nav1.7 inhibitor, PF-05198007 (1 and 10mg/kg) reduced the flare response to
capsaicin for the duration of the observation period (55 mins; Vehicle; 4930 ± 751 versus 1 and
Fig 7. PF-05198007 reduces the capsaicin flare response in WT, but not Nav1.7
Nav1.8Cre mice. A, B.
Time-course plots showing the effects of PF-05198007 on skin blood flow measured before and after topical
capsaicin application for WT (A) and Nav1.7Nav1.8Cre (B) mice (for each genotype, n = 8 per group). C, D.
Corresponding summary bar graphs showing flare response measured as area under the curve for WT (C)
and Nav1.7Nav1.8Cre (D) mice before and after PF-05198007 treatment. 1 mg/kg and 10 mg/kg PF-05198007
significantly reduced capsaicin-induced flare in WTmice (C, both 1 mg/kg and 10 mg/kg, p < 0.01, ANOVA)
but had no effect in Nav1.7
Nav1.8Cre mice (D, both 1 mg/kg and 10 mg/kg, p > 0.05, ANOVA).
doi:10.1371/journal.pone.0152405.g007
Selective Inhibitors Reveal Role of Nav1.7 in Nociceptor Physiology
PLOS ONE | DOI:10.1371/journal.pone.0152405 April 6, 2016 16 / 22
10 mg/kg 1967 ± 472 and 2265 ± 382, respectively (n = 7), AUC, p< 0.05, Fig 7A). To confirm
that Nav1.7 block underlied this effect, we repeated the experiment using Nav1.7
Nav1.8 Cre mice
in which Nav1.7 is genetically deleted only in Nav1.8-positive nocicetors (Nasser et al., 2004).
Application of capsaicin to Nav1.7
Nav1.8 Cre mice resulted in a reduced (AUC, p< 0.01 vsWT,
Fig 7B)—albeit still statistically significant—flare response (AUC, p< 0.05 vs pre-capsaicin
baseline). Importantly, the flare response in Nav1.7
Nav1.8 Cre mice was indistinguishable from
the residual flare response in WT PF-05198007-treated mice. PF-05198007 (1, 10 mg/kg), had
no effect on the flare response in Nav1.7
Nav1.8 Cre mice (for both doses, p> 0.05, Fig 7B) indi-
cating that the Nav1.7 component of flare in WT mice was completely blocked by the selective
Nav1.7 inhibitor whilst other mechanisms that contribute to flare remained unaffected. These
data demonstrate a Nav1.7-mediated contribution to neuropeptide release in peripheral neuro-
genic flare.
Discussion
There recently has been intense interest in development of subtype-selective Nav1.7 inhibitors.
This has arisen from the identification of gain-of-function mutations of Nav1.7 in individuals
with rare pain syndromes IEM, PEPD and the more common disorder SFN, as well as the dis-
covery of this channel’s link to channelopathy-associated congenital insensitivity to pain.
Together, this constellation of gain-of-function and loss-of-function mutations demonstrates
an essential and non-redundant role for Nav1.7 in pain [1]. Here we describe in vitro pharma-
cological properties of two subtype-selective Nav1.7 compounds: a clinical compound PF-
05089771 and a structurally-related preclinical tool compound PF-05198007. Using these
selective inhibitors we have confirmed a functional role of Nav1.7 that spans the sensory neu-
ron axis—from the cutaneous free nerve endings, through to the DRG cell body, dorsal root
and central terminals in the spinal cord.
Pharmacological properties of Nav1.7 subtype-selective compounds
The potency of PF-05089771 against human Nav1.7 channels stably expressed in HEK293 cells
(IC50, 11 nM) was 10-fold and 16-fold higher than the closest sodium channel isoforms Nav1.2
and Nav1.6, respectively. Other sodium channel subtypes that have been shown to play impor-
tant roles in the pain pathways and that are expressed in DRG neurons, Nav1.3 and Nav1.8
[26], are essentially unaffected by PF-05089771. A lack of validated heterologous expression
system for Nav1.9 prohibited evaluation of the potency of PF-05089771 against this channel,
which has been shown to play an important role in human pain conditions [27]. The potency
and selectivity of PF-05089771 have been achieved by targeting a novel binding region of
Nav1.7 proposed to be in the VSD4 [22,28]. The interaction of PF-05089771 with this novel
binding site is further supported by the inability of mutations altering the local anesthetic and
TTX binding sites in Nav1.7 to significantly alter the potency of PF-05089771 examined in
vitro. The selectivity gained through interacting with the channel at this site is consistent with
the variability of critical amino acids across sodium channel isoforms, supporting a modulatory
effect of PF-05089771 on the VSD of Nav1.7. Finally, this is also the case for several species
orthologues of Nav1.7 where PF-05089771 was found to preferentially inhibit human, mouse,
cynomolgus monkey and dog Nav1.7 over rat Nav1.7. The rat orthologue possesses two variant
residues at the VSD4 interaction site and uniquely displays a histidine residue at position M1,
differentiating rat from the other species that were tested. Thus, the unprecedented selectivity
profile achieved by PF-05089771 and the cross-species differences in Nav1.7 orthologue
potency can be explained through the novel binding interaction of this class of compounds.
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Nav1.7 dominates TTX-S current in small-diameter DRG neurons
Several lines of evidence have suggested that Nav1.7 is the predominant Nav TTX-S subtype
expressed in C-fibres, while Nav1.7, Nav1.6 and Nav1.1 are the main TTX-S subtypes present in
A-fibres [29] [11] [26] [30] [12] [1] [13]. Using RNA-Seq to analyse pooled small-diameter
mouse DRG neurons, we also demonstrate that Nav1.7 is the major TTX-S subtype transcript
in nociceptors. We found that high Nav1.7 expression translates at the functional level because
the majority of the isolated TTX-S current in the cell body of small-diameter mouse and
human DRG neurons was blocked by Nav1.7 inhibitors. This data is consistent with published
work showing that TTX-S current in small-diameter DRG neurons from the Nav1.7
Nav1.8 Cre
mouse is reduced by 70% compared to WT [31]. Taken together, these findings imply that
Nav1.7 is likely to play a prominent role in nociceptor excitability.
The role of Nav1.7 in electrogenesis
Our electrophysiological studies demonstrate the important contribution of Nav1.7 to both
mouse and human sensory neuron action potential firing. In particular, the effects of Nav1.7
inhibitors on mouse DRG rheobase provide the first pharmacological evidence using a small
molecule selective inhibitor that native Nav1.7 acts as the threshold channel. These data are
consistent with recorded changes in rheobase following Nav1.7 silencing in cultured nodose
sensory neurons [32] and dynamic clamp analysis, using a Hodgkin-Huxley model of hNav1.7
gating [31]. Furthermore our observation of a reduction in action potential peak height and
slope in the presence of PF-05198007 suggests a role for Nav1.7 in the upstroke of the action
potential, in addition to the more accepted idea of Nav1.7 as a threshold channel. Indeed, using
the action potential voltage-clamp technique [33] we found that Nav1.7 conducts during the
upstroke as well as the during initiation stage of the action potential. Although Nav1.7 has been
suggested to amplify the generator potential at the peripheral terminals thus acting a s a thresh-
old channel [24], we propose that another principal role for Nav1.7 in nociceptors is in action
potential electrogenesis.
Central and peripheral role of Nav1.7 in nociceptors
The role of Nav1.7 in synaptic transmission within the spinal cord was addressed using patch-
clamp recordings from dorsal horn SG neurons following stimulation of the dorsal root.
Evoked EPSCs were significantly reduced in amplitude by PF-05198007 perfused over the
entire spinal cord slice preparation. These findings agree with previous reports demonstrating
reduced Substance P release from spinal cord slices of Nav1.7 knockout mice (Nav1.7 ablated in
advillin-expressing neurons) following electrical stimulation of attached dorsal root [34] and
the reduced frequency of spontaneous EPSCs in mouse lamina II neurons following the appli-
cation of a Nav1.7 blocking antibody [35]. In addition, a central role of Nav1.7 has been demon-
strated in vivo where a reduction in pain behaviour in mice is observed following intrathecal
injection of this antibody [35]. In this scenario, Nav1.7 block can occur at both dorsal root and
outer laminae. Here, the specific contributions of Nav1.7 to both conduction and synaptic
release in the spinal cord were further investigated using PF-5198007. Specifically, we observed
a reduction in C-fibre mediated EPSC amplitudes recorded from SG neurons (with corre-
sponding slowing of C-fibre conduction velocity) following local application of PF-05198007
to dorsal root, implicating Nav1.7 in axonal conduction. In support of this, significant block of
A-and C-fibre action potentials in vagal sensory neurons has been reported following shRNA
knockdown of Nav1.7 [32] and similar findings have been obtained from sciatic nerve in stud-
ies using toxins that selectively inhibit different Nav subtypes including Nav1.7 [36] [37]. Col-
lectively, these data are consistent with a role for Nav1.7 in which it influences synaptic
Selective Inhibitors Reveal Role of Nav1.7 in Nociceptor Physiology
PLOS ONE | DOI:10.1371/journal.pone.0152405 April 6, 2016 18 / 22
transmission in the dorsal horn via actions either at a peripheral location (i.e. by facilitating or
permitting conduction), or at a central location (i.e. by affecting CGRP/Substance P release
from central terminals), or both.
TRPV1 expression has previously been shown to be limited to C-fibres in mouse [38] [39]
[13]. Therefore, neurogenic flare induced by topical application of a non-noxious dose of cap-
saicin represents a C-fibre mediated mechanism in mouse. Using the Laser Doppler flowmetry
to measure increased blood flow associated with peripherally mediated axon reflex vasodilation
[40], capsaicin-induced neurogenic flare was suppressed by the Nav1.7 inhibitor PF-05198007
in wild-type mouse, but this inhibitor had no effect on the Nav1.7
Nav1.8Cre knock-out mouse at
the same dose. These data suggest a key role of Nav1.7 in controlling neuropeptide release from
peripheral terminals of peptidergic C-fibres and potentially a role in conduction associated
with the axon reflex.
Conclusion
The data in the current study could be interpreted as supporting separate roles for Nav1.7 in
neurogenic flare, conduction and presynaptic release. However, peptidergic terminals in the
dorsal horn consist of en passant varicosities [41] giving rise to simple non-glomerular axo-
dendritic synapses [42]. Voltage-gated sodium channels have also been identified in en passant
varicosities of both posterior pituitary and mossy fibre terminals, where they have been sug-
gested to contribute to action potential generation and conduction [43] [44]. Therefore, a sim-
ple unifying theory, which takes into account the clear role of Nav1.7 in action potential
generation at multiple sites, is that Nav1.7 contributes to electrogenesis at, or close to, distal ter-
minals in peripheral axon, in the dorsal root and at, or close to, neurotransmitter-releasing
boutons of nociceptors. The development and availability of selective Nav1.7 inhibitors will aid
future studies to delineate the interplay between Nav1.7 function and nociceptor signalling in
both acute and chronic pain states.
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